A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Samaraweera, Leleesha ^a   Adomako, Alfred ^a   Rodriguez Gabin, Alicia ^a   McDaid, Hayley M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL; PANOBINOSTAT;

APOPTOSIS; CELL AGING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CELLULAR SENESCENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PANOBINOSTAT; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK;

EID: 85019464334     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01964-1     Document Type: Article

References (44)

1. Zarogoulidis, K. et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 5 Suppl 4, S389-396, doi:10.3978/j.issn.2072-1439.2013.07.10 (2013).
2. Sacco, A. G. & Cohen, E. E. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 33, 3305-3313, doi:10.1200/JCO.2015.62.0963 (2015).
3. West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation 124, 30-39, doi:10.1172/JCI69738 (2014).
4. Xu, W. S., Parmigiani, R. B. & Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552, doi:10.1038/sj.onc.1210620 (2007).
5. F.D.A., U. S. F. a. D. A. FDA approves Farydak for treatment of multiple myeloma (2015).
6. Haigentz, M. Jr. et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 48, 1281-8, doi:10.1016/j.oraloncology.2012.05.024 (2012).
7. Gray, J. E. et al. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 20, 1644-1655, doi:10.1158/1078-0432.CCR-13-2235 (2014).
8. Takhar, H. S. et al. Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Anticancer Drugs 26, 1069-1077, doi:10.1097/ CAD.0000000000000282 (2015).
9. Ramalingam, S. S. et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28, 56-62, doi:10.1200/JCO.2009.24.9094 (2010).
10. Qiu, T. et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 9, 255-269, doi:10.2217/fon.12.173 (2013).
11. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55, doi:10.1016/0065-2571(84)90007-4 (1984).
12. Prystowsky, M. et al. Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G(2) Delay and Mitotic Defects. Scientific Reports 3, 2640, doi:10.1038/srep02640 (2013).
13. Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522, doi:10.1016/j. cell.2005.02.003 (2005).
14. Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114, 1299-1307, doi:10.1172/JCI22475 (2004).
15. Coppé, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression. Annual Review of Pathology: Mechanisms of Disease 5, 99-118, doi:10.1146/annurev-pathol-121808-102144 (2010).
16. Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232-236, doi:10.1038/nature10600 (2011).
17. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78-83, doi:10.1038/nm.4010 (2016).
18. Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644-658, doi:10.1111/ acel.12344 (2015).
19. Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428-435, doi:10.1111/acel.12445 (2016).
20. Li, M. et al. Oncogene-induced cellular senescence elicits an anti-Warburg effect. Proteomics 13, 2585-2596, doi:10.1002/ pmic.201200298 (2013).
21. Bauer, S. et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 110, 1155-1162, doi:10.1038/bjc.2013.826 (2014).
22. Munster, P. N. et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104, 1828-1835, doi:10.1038/bjc.2011.156 (2011).
23. Rada-Iglesias, A. et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 17, 708-719, doi:10.1101/gr.5540007 (2007).
24. Duan, H., Heckman, C. A. & Boxer, L. M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25, 1608-1619, doi:10.1128/MCB.25.5.1608-1619.2005 (2005).
25. Frys, S. et al. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol 169, 506-519, doi:10.1111/bjh.13318 (2015).
26. Chao, H. et al. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway. Cancer Lett 329, 17-26, doi:10.1016/j.canlet.2012.08.035 (2012).
27. Modesitt, S. C. & Parsons, S. J. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter Gynecol Oncol 119, 351-357, doi:10.1016/j.ygyno.2010.06.030 (2010).
28. Zuco, V. et al. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS ONE 6, e29085, doi:10.1371/journal.pone.0029085 (2011).
29. Dowdy, S. C. et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5, 2767-2776, doi:10.1158/1535-7163.MCT-06-0209 (2006).
30. Chao, S. K. et al. Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc Natl Acad Sci USA 108, 391-396, doi:10.1073/pnas.1016962108 (2011).
31. Gosselin, K. et al. Senescence-Associated Oxidative DNA Damage Promotes the Generation of Neoplastic Cells. Cancer Research 69, 7917-7925, doi:10.1158/0008-5472.CAN-08-2510 (2009).
32. Laberge, R.-M., Awad, P., Campisi, J. & Desprez, P.-Y. Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts. Cancer Microenvironment 5, 39-44, doi:10.1007/s12307-011-0069-4 (2012).
33. Kang, T.-W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551, doi:10.1038/nature10599 (2011).
34. Lujambio, A. To clear, or not to clear (senescent cells) That is the question. Inside the Cell 1, 87-95, doi:10.1002/icl3.1046 (2016).
35. Cao, X. X., Mohuiddin, I., Ece, F., McConkey, D. J. & Smythe, W. R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25, 562-568, doi:10.1165/ajrcmb.25.5.4539 (2001).
36. Zhang, W. et al. Histone modifications contribute to cellular replicative and hydrogen peroxide-induced premature senescence in human embryonic lung fibroblasts. Free Radic Res 48, 550-559, doi:10.3109/10715762.2014.893580 (2014).
37. Munster, P. et al. Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clinical Cancer Research 15, 2488-96, doi:10.1158/1078-0432.CCR-08-1930 (2009).
38. Arce, C. et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 1, e98, doi:10.1371/journal.pone.0000098 (2006).
39. Komlodi-Pasztor, E., Sackett, D., Wilkerson, J. & Fojo, T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8, 244-250, doi:10.1038/nrclinonc.2010.228 (2011).
40. Mitchison, T. J. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23, 1-6, doi:10.1091/mbc.E10-04-0335 (2012).
41. Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18, 1359-68, doi:10.1038/nm.2890 (2012).
42. Sidi, R. et al. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur J Cancer 47, 326-332, doi:10.1016/j.ejca.2010.09.044 (2011).
43. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1, 1112-1116, doi:10.1038/ nprot.2006.179 (2006).
44. Itahana, K., Campisi, J. & Dimri, G. P. Methods to detect biomarkers of cellular senescence: the senescence-associated betagalactosidase assay. Methods Mol Biol 371, 21-31, doi:10.1007/978-1-59745-361-5 (2007).